{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:05:49Z","timestamp":1760551549037,"version":"3.40.5"},"reference-count":50,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2016\/05624\u20100","2018\/05616\u20103"],"award-info":[{"award-number":["2016\/05624\u20100","2018\/05616\u20103"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["303142\/2019\u20107"],"award-info":[{"award-number":["303142\/2019\u20107"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There are contrasting findings regarding the effect of HIV on the pharmacokinetics of first\u2010line anti\u2010tubercular drugs (FLATDs) due to a lack of prospective controlled clinical studies, including patients with tuberculosis (TB) and patients with TB living with HIV. This study aims to assess the effect of HIV coinfection and antiviral therapy on the plasma exposure to FLATDs in patients with TB. HIV negative (TB\u2010HIV\u2212 group; <jats:italic>n<\/jats:italic> = 15) and HIV positive (TB\u2010HIV+ group; <jats:italic>n<\/jats:italic> = 18) adult patients with TB were enrolled during the second month of FLATDs treatment. All TB\u2010HIV+ patients were on treatment with lamivudine, tenofovir (or zidovudine), and raltegravir (or efavirenz). Serial blood sampling was collected over 24\u00a0h and FLATDs pharmacokinetic parameters were evaluated using noncompartmental methods. In the TB\u2010HIV+ patients, dose\u2010normalized plasma exposure area under the curve from zero to 24 h (nAUC<jats:sub>0\u201324<\/jats:sub>; geometric mean and 95% confidence interval [CI]) values at steady\u2010state to rifampicin, pyrazinamide, and ethambutol were 18.38 (95% CI 13.74\u201324.59), 238.21 (95% CI 191.09\u2013296.95), and 18.33 (95% CI 14.56\u201323.09) \u00b5g\u2219h\/ml, respectively. Similar plasma exposure was found in the TB\u2010HIV\u2212 patients. The geometric mean and 90% CI of the ratios between TB\u2010HIV\u2212 and TB\u2010HIV+ groups suggest no significant pharmacokinetic interaction between the selected antivirals and FLATDs. Likewise, HIV coinfection itself does not appear to have any effect on the plasma exposure to FLATDs.<\/jats:p>","DOI":"10.1111\/cts.13169","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T13:36:22Z","timestamp":1634823382000},"page":"514-523","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients"],"prefix":"10.1111","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7024-4252","authenticated-orcid":false,"given":"Glauco Henrique Balthazar","family":"Nardotto","sequence":"first","affiliation":[{"name":"Faculdade de Ci\u00eancias Farmac\u00eauticas de Ribeir\u00e3o Preto Universidade de S\u00e3o Paulo  Ribeir\u00e3o Preto Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8221-4701","authenticated-orcid":false,"given":"Valdes Roberto","family":"Bollela","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Ribeir\u00e3o Preto Universidade de S\u00e3o Paulo  Ribeir\u00e3o Preto Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Rocha","sequence":"additional","affiliation":[{"name":"Faculdade de Ci\u00eancias Farmac\u00eauticas de Ribeir\u00e3o Preto Universidade de S\u00e3o Paulo  Ribeir\u00e3o Preto Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6211-1430","authenticated-orcid":false,"given":"Oscar","family":"Della Pasqua","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology &amp; Therapeutics Group School of Pharmacy \u2013 University College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0074-4953","authenticated-orcid":false,"given":"Vera Lucia","family":"Lanchote","sequence":"additional","affiliation":[{"name":"Faculdade de Ci\u00eancias Farmac\u00eauticas de Ribeir\u00e3o Preto Universidade de S\u00e3o Paulo  Ribeir\u00e3o Preto Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"volume-title":"Global Tuberculosis Report","year":"2020","author":"World Health Organization","key":"e_1_2_9_2_1"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1086\/651492"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198903023200901"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70093-1"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.151.1.7812542"},{"key":"e_1_2_9_7_1","first-page":"1","volume-title":"Manual de recomenda\u00e7\u00f5es para o controle da tuberculose no brasil","author":"Minist\u00e9rio da Sa\u00fade","year":"2019"},{"key":"e_1_2_9_8_1","first-page":"1","volume-title":"International Standards for Tuberculosis Care","author":"TB CARE I","year":"2014"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.180"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0222-8"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.5.1178"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.5.1520"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-4-199708150-00006"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002773"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.5588\/09640569513002"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-015-9438-9"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0716-8"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.183"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2083-4"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.339"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1221"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz319"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2017.1311323"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02278-15"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6901a1"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70711-X"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241090-00004"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit246"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.11.4473-4475.2004"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1170-1177.2006"},{"issue":"8","key":"e_1_2_9_31_1","first-page":"670","article-title":"Does AIDS impair the absorption of antituberculosis agents?","volume":"2","author":"Taylor B","year":"1998","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01193-15"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00480-16"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.646"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x20154458"},{"issue":"6","key":"e_1_2_9_36_1","first-page":"405","article-title":"Emergence of dual antiretroviral therapy as a viable regimen option for the treatment of patients with HIV infection","volume":"56","author":"Fida M","year":"2020","journal-title":"Drugs Today Barc Spain 1998"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1021\/id500028m"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-00536-y"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2012.09.042"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-0711-5-3"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt036"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01833-10"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa328"},{"volume-title":"Raltegravir assessment report","author":"Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (EMA)","key":"e_1_2_9_45_1"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2010.09.012"},{"volume-title":"Lamivudine assessment report","author":"European Medicines Agency (EMA)","key":"e_1_2_9_47_1"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00046-21"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1086\/599040"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06059-11"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit352"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13169","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.13169","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T03:15:16Z","timestamp":1692501316000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,20]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1111\/cts.13169"],"URL":"https:\/\/doi.org\/10.1111\/cts.13169","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"type":"print","value":"1752-8054"},{"type":"electronic","value":"1752-8062"}],"subject":[],"published":{"date-parts":[[2021,10,20]]},"assertion":[{"value":"2021-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}